Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 4/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25552167 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL13146707 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL15820005 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL15038839 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL12146652 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL17598292 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL24652905 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL12968428 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL18018239 | 0.87 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL21441809 | 0.87 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HSD17B10PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385097-B2 | Ether compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180072762-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170057993-A1 | Ether Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-8574563-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2010117635-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7812178-B2 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-12 | — | — | US | disclosed |
| US-20090076276-A1 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-19 | — | — | US | disclosed |
| US-7459465-B2 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-12-02 | — | — | US | disclosed |
| US-20070161620-A1 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7220759-B2 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20040248931-A1 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | CHRM2 4738/4885CHRM1 4748/4885CHRM3 4012/4885 |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | CHRM2 2731/4885CHRM1 3155/4885CHRM3 3429/4885 |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CHRM2 4881/4885CHRM1 4856/4885CHRM3 4838/4885 |
| US-20040248931-A1 | Isoquinoline compound and pharmaceutical use thereof | NQO1, PARP1, PARP11 | CHRM2 4189/4885CHRM1 3425/4885CHRM3 3864/4885 |
| US-20170057993-A1 | Ether Compounds for Treatment of Medical Disorders | CFD, TFPI, F12 | CHRM2 2985/4885CHRM1 3159/4885CHRM3 3785/4885 |
| US-10385097-B2 | Ether compounds for treatment of medical disorders | CFD, TFPI, F12 | CHRM2 2985/4885CHRM1 3159/4885CHRM3 3785/4885 |
| US-20090076276-A1 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF | NQO1, PARP1, NUDT1 | CHRM2 4263/4885CHRM1 3783/4885CHRM3 3855/4885 |
| US-20180072762-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | CHRM2 1152/4885CHRM1 1408/4885CHRM3 1609/4885 |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CHRM2 4881/4885CHRM1 4856/4885CHRM3 4838/4885 |
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | CHRM2 3967/4885CHRM1 4134/4885CHRM3 4554/4885 |
| US-20070161620-A1 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF | NQO1, PARP1, NUDT1 | CHRM2 4263/4885CHRM1 3783/4885CHRM3 3855/4885 |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | CFD, TFPI, CFH | CHRM2 3967/4885CHRM1 4134/4885CHRM3 4554/4885 |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CHRM2 4697/4885CHRM1 4713/4885CHRM3 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.